CoChat
Sign Up
Cited by 327

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

How do anti-mitotic drugs kill cancer cells?

Gascoigne, Karen E., Taylor, Stephen S.·2009·Journal of Cell Science
DOI 10.1242/jcs.039719
Open this paper in CoChat — free account

Abstract

In 2007, over 12-million people were diagnosed with cancer. According to the American Cancer Society, at least one third of these individuals are not expected to survive the disease, making cancer the second most prevalent cause of death worldwide. Systemic chemotherapy forms the mainstay of cancer treatment, and agents that disrupt mitotic spindle assembly – so called `anti-mitotics' – are commonly used to treat a wide variety of cancers. Traditional anti-mitotic agents include the microtubule toxins such as taxol, other taxanes and the vinca alkaloids, all of which have proven successful in the clinic. However, patient response remains highly unpredictable, and drug resistance is common. In addition, toxicity is a problem. To address these limitations, a new generation of anti-mitotic drugs is being developed. As the first wave of these new agents enters clinical trails, much hope rests on their outcome. Meanwhile, significant attention is being focused on trying to predict which tumour types are likely to respond. In this Commentary, we outline recent advances in our understanding of how cancer cells respond to anti-mitotic drugs, and discuss the relevance of these studies to their use in the clinic.

Overview

Integrity signals

Registry

Crossref · 10.1242/jcs.039719

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 34

  1. Allan, L. A. and Clarke, P. R. (2007). Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol. Cell26, 301-310. · DOI
  2. Bergnes, G., Brejc, K. and Belmont, L. (2005). Mitotic kinesins: prospects for antimitotic drug discovery. Curr. Top. Med. Chem.5, 127-145. · DOI
  3. Brinkley, B. R. (2001). Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol.11, 18-21. · DOI
  4. Brito, D. A. and Rieder, C. L. (2006). Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol.16, 1194-1200. · DOI
  5. Brito, D. A. and Rieder, C. L. (2008). The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil. Cytoskeleton (in press). doi:10.1002/cm.20316. · DOI
  6. Brito, D. A., Yang, Z. and Rieder, C. L. (2008). Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J. Cell Biol.182, 623-629. · DOI
  7. Gascoigne, K. E. and Taylor, S. S. (2008). Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell14, 111-122. · DOI · Paper page
  8. Holland, A. J. and Cleveland, D. W. (2008). Beyond genetics: surprising determinants of cell fate in antitumor drugs. Cancer Cell14, 103-105. · DOI
  9. Jordan, M. A. and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat. Rev. Cancer4, 253-265. · DOI · Paper page
  10. Jordan, M. A., Toso, R. J., Thrower, D. and Wilson, L. (1993). Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA90, 9552-9556. · DOI · Paper page
  11. Karlsson, M. O., Molnar, V., Freijs, A., Nygren, P., Bergh, J. and Larsson, R. (1999). Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab. Dispos.27, 1220-1223. · DOI
  12. Keen, N. and Taylor, S. (2004). Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer4, 927-936. · DOI
  13. Keen, N. and Taylor, S. (2009). Mitotic drivers-inhibitors of the Aurora B Kinase. Cancer Metastasis Rev.28, 185-195. · DOI
  14. Klein, E., Debonis, S., Thiede, B., Skoufias, D. A., Kozielski, F. and Lebeau, L. (2007). New chemical tools for investigating human mitotic kinesin Eg5. Bioorg. Med. Chem.15, 6474-6488. · DOI
  15. Knox, J. J., Gill, S., Synold, T. W., Biagi, J. J., Major, P., Feld, R., Cripps, C., Wainman, N., Eisenhauer, E. and Seymour, L. (2008). A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest. New Drugs26, 265-272. · DOI
  16. Kwon, M., Godinho, S. A., Chandhok, N. S., Ganem, N. J., Azioune, A., Thery, M. and Pellman, D. (2008). Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev.22, 2189-2203. · DOI
  17. Lanni, J. S. and Jacks, T. (1998). Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol.18, 1055-1064. · DOI
  18. Lee, C. W., Belanger, K., Rao, S. C., Petrella, T. M., Tozer, R. G., Wood, L., Savage, K. J., Eisenhauer, E. A., Synold, T. W., Wainman, N. et al. (2008). A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest. New Drugs26, 249-255. · DOI
  19. McGrogan, B. T., Gilmartin, B., Carney, D. N. and McCann, A. (2008). Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta1785, 96-132. · DOI
  20. Milross, C. G., Mason, K. A., Hunter, N. R., Chung, W. K., Peters, L. J. and Milas, L. (1996). Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst.88, 1308-1314. · DOI
  21. Niikura, Y., Dixit, A., Scott, R., Perkins, G. and Kitagawa, K. (2007). BUB1 mediation of caspase-independent mitotic death determines cell fate. J. Cell Biol.178, 283-296. · DOI
  22. Nogales, E. (2000). Structural insights into microtubule function. Annu. Rev. Biochem.69, 277-302. · DOI
  23. Orth, J. D., Tang, Y., Shi, J., Loy, C. T., Amendt, C., Wilm, C., Zenke, F. T. and Mitchison, T. J. (2008). Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol. Cancer Ther.7, 3480-3489. · DOI
  24. Rai, S. S. and Wolff, J. (1996). Localization of the vinblastine-binding site on beta-tubulin. J. Biol. Chem.271, 14707-14711. · DOI
  25. Rieder, C. L. and Maiato, H. (2004). Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell7, 637-651. · DOI
  26. Rowinsky, E. K. (1997). The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med.48, 353-374. · DOI
  27. Schiff, P. B., Fant, J. and Horwitz, S. B. (1979). Promotion of microtubule assembly in vitro by taxol. Nature277, 665-667. · DOI · Paper page
  28. Schimming, R., Mason, K. A., Hunter, N., Weil, M., Kishi, K. and Milas, L. (1999). Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother. Pharmacol.43, 165-172. · DOI
  29. Schwartz, E. L. (2009). Antivascular actions of microtubule-binding drugs. Clin. Cancer Res.15, 2594-2601. · DOI
  30. Shi, J., Orth, J. D. and Mitchison, T. (2008). Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res.68, 3269-3276. · DOI
  31. Strebhardt, K. and Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer6, 321-330. · DOI
  32. Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., Schwarz, J. K., Pond, G. R., Johnson, C., Colevas, A. D., Synold, T. W. et al. (2008). Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs26, 257-264. · DOI
  33. Tao, W., South, V. J., Zhang, Y., Davide, J. P., Farrell, L., Kohl, N. E., Sepp-Lorenzino, L. and Lobell, R. B. (2005). Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell8, 49-59. · DOI
  34. Weaver, B. A. and Cleveland, D. W. (2005). Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell8, 7-12. · DOI

Cited by

Sorted by citations

Metadata

Authors
Gascoigne, K. E., & Taylor, S. S.
Affiliations
Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK
Venue
Journal of Cell Science
Publisher
The Company of Biologists
Published
2009-08-01
Volume
122
Issue
15
Pages
2579-2585
ISSN
  • 1477-9137
  • 0021-9533
DOI
10.1242/jcs.039719
Cited by
327
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review